[A 19-year-old genius invents a new drug, and a pharmaceutical company spends $300 million to buy a patent]

This kind of news is not fueled by the media, when the drug has not yet been officially launched and caused a social sensation, and when both buyers and sellers are relatively low-key.

The news went viral in some newspapers for a few days, making some people remember the names Abel Sephorosa and Pfizer.

Gradually, it died down.

Entering this year of 1990, the whole world is about to gradually enter an era of information explosion. At this time, the United States, which undoubtedly leads the world in various aspects of science and technology, has already appeared as a prelude to an information explosion.

Ordinary people have more and more channels and can see more and more information. In such a situation, even a high-profile piece of news can be found without a constant push.

Then soon its popularity will go down, and the attention span of ordinary people is limited, and they will naturally be attracted by other news and information that will emerge in the past.

In this way, the news becomes old news.

It's just a few days.

The names of Abel Sephorosa and Pfizer gradually disappeared from the media and newspapers.

But.

Just because the media don't pay attention doesn't mean that the pharmaceutical companies that know about it don't pay attention.

The news that Pfizer has purchased a new drug patent for a medical genius has spread rapidly in the industry.

At this time, some specific information about the future Viagra, now scientifically named sildenafil, was also sent to the desks of the presidents of major pharmaceutical companies under the attention of those who care.

In this industry, everyone is a competitor. Naturally, I will also pay attention to the latest technology of competitors, and if I can imitate or copy the other party's front of each other and develop new drugs faster, of course, it will be better.

In the case of the imperfect patent barriers of the other party, such things happen in the pharmaceutical industry every day of the year, every month.

When it comes to the most profitable and low-key industries, the pharmaceutical industry is definitely one of the leaders.

A bottle of a drug that costs a few cents can be sold for tens of dollars in the hands of a patient who needs it.

That's hundreds of times the profit.

Even a new drug, from research to production, often takes hundreds of millions of dollars and a few years at the very least, and the investment is huge and terrifying.

But with exaggerated explosive profits ahead, it is natural that someone will come crazy with such an investment.

Don't look at the pharmaceutical industry is very low-key, but in the future of the world's top 500 list, the pharmaceutical industry occupies at least more than 20. This is still a situation where many countries do not care or deliberately do not care about pharmaceutical patents, if all countries in the world attach as much importance to pharmaceutical patents as the United States.

The profits of the pharmaceutical industry are estimated to more than double.

The simplest example.

Generic drugs in the three countries.

If they can knock out the generic drugs in their country, it is estimated that the profits of pharmaceutical companies all over the world can double.

On the seventh day after Abel sold the patent.

Bristol-Myers Squibb, New York headquarters.

Bristol-Myers Squibb is a global scientific research focused diversified company engaged in healthcare and personal care products, including pharmaceutical products, consumer goods, nutrition and medical devices.

The company has been in the United States for more than 100 years, and today in 1990, it has grown into a global diversified enterprise with annual sales of more than $10 billion, more than 120 countries and more than 44,000 employees in more than 120 countries around the world, and the company is headquartered in New York.

It was also the world's largest giant in the world's pharmaceutical industry in terms of sales in 1989.

In the present, it is undoubtedly glorious and brilliant. It's just that 30 years later, it is now the world's No. 1, but it is no longer in the top 10 of the global pharmaceutical company rankings.

Headquarters.

Antonio Johnson was in the hallway, and the president of the company called him to look for him in the office.

And the reason.

His daughter, the wife of one of the company's shareholders, had already told him last night.

It was the same event that happened seven days ago, when Antonio Johnson, as a representative of the company, traveled to Silicon Valley to meet a young medical genius.

Then.

Just arrived in Silicon Valley, in the conference room of the Hilton Hotel at San Francisco Airport, Antonio Johnson began to be dissatisfied when he arrived in the conference room.

Because he found that the young man who had asked him to meet was very proud and arrogant.

He was not the only one who met together, there were also people from Pfizer and Merck, and even one person.

What does this kid want to do?

Did he think he was a strange commodity?

As an old fritter in the industry, or a middle and senior manager of Bristol-Myers Squibb, the world's No. 1 pharmaceutical company, when has Antonio Johnson been treated like this unknown person in the pharmaceutical industry?!

In the past, those so-called young medical geniuses, those college students who had just graduated from those famous universities, which one came to Bristol-Myers Squibb to interview for a job, and didn't it be respectful to meet him?!

This time it's good.

The son of the real estate merchant actually neglected him like this, which made him unhappy.

This also made him still have some arrogance in his later work, and he was finally kicked out.

After Antonio Johnson returned to the company, he also reported to his superiors that Abel Sephorosa was just a liar who deceived the world and stole his reputation, and some geniuses and the like were all blown out.

His boss, although he thinks that the genius who can be praised by the Nobel Prize winner in medicine, should not be a parallel import.

But seeing that Antonio Johnson was right, he believed his boss without doubt.

It didn't take a few days.

Within the pharmaceutical industry, it is rumored that Pfizer spent $300 million to obtain a patent for a new drug.

Some of the technical information of the new drug patent was found by someone who was interested in it, and it was found that it was such a good thing, and the market prospect was huge.

Antonio's boss sighed at the time that Pfizer, a second-tier pharmaceutical company, was really lucky this time, and actually bought such a patent!

Then check it out later.

Antonio's boss, with a dark face, found out that Bristol-Myers Squibb also had a chance to obtain the patent for this promising new drug.

And this good opportunity was lost to the idiot Antonio Johnson!

And so.

Antonio Johnson was called into the company today, and even went straight to the president and asked him to meet the company's president.

And when he entered the office of Mr. President, His Excellency Sharon Lokaeff Williams, President and CEO of Bristol-Myers Squibb in 1990, gave him an order:

Invite that young medical genius to work at Bristol-Myers Squibb!

If you can't get invited.

Ask Antonio Johnson to get out of Bristol-Myers Squibb!